Clinical trials: Refractory Solid Tumors
Refractory Solid Tumors
Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment
The purpose of this study is to evaluate the safety of an experimental drug (p28) as a treatment for certain advanced cancers which express a protein called p53 and which have not responded to prior treatment.
- Trial name
- NCT00914914
- Testing
- p28
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dr. Tapas K. Das Gupta
Multiple Myeloma, Advanced Solid Tumors
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants…
- Trial name
- NCT01830816
- Testing
- Ixazomib
- Where
- 11 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor, Cancer
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8).
- Conditions
- Solid Tumor, Cancer, Recurrent Solid Tumors, Refractory Solid Tumors
- Trial name
- ACTengine (NCT03247309)
- Testing
- IMA201 Product, IMADetect®
- Where
- 5 sites in United States, Germany
- Volunteers
- 7 people
- Sponsor
- Immatics US, Inc.
Solid Tumors, Colorectal Cancer
L19TNFα in Patients With Advanced Solid Tumors
The recombinant human fusion protein L19TNFα was created with the intention to overcome the systemic toxicity of TNFα by directly targeting it to tumor tissues.
- Trial name
- NCT01253837
- Testing
- L19TNFa
- Where
- 2 sites in Italy
- Volunteers
- 34 people
- Sponsor
- Philogen S.p.A.
Advanced Solid Tumors
Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design to determine maximum tolerated dose/recommended Phase 2 dose.
- Trial name
- NCT00734305
- Testing
- MM-121
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Merrimack Pharmaceuticals
Hepatocellular Carcinoma, Non-small Cell Lung Cancer
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
- Conditions
- Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Pancreatic Carcinoma, Triple-Negative Invasive Breast Carcinoma
- Trial name
- NCT02839954
- Testing
- anti-MUC1 CAR-pNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Neoplasms
Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
This will be an uncontrolled, open-label, non-randomized, phase I study. The primary objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety and tolerability of Regorafenib administered orally…
- Trial name
- NCT01096030
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 33 people
- Sponsor
- Bayer
Unspecified Adult Solid Tumor, Protocol Specific
Phenoxodiol in Treating Patients With Refractory Solid Tumors
RATIONALE: Phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of phenoxodiol in treating patients who have refractory solid…
- Trial name
- NCT00022295
- Testing
- idronoxil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kazia Therapeutics Limited
Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma
RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER
This proposed first-in-human study (408-C-1303) is designed to assess the safety, maximum tolerated dose, pharmacodynamics, and pharmacokinetics of omaveloxolone (RTA 408) in patients with advanced solid tumors that are…
- Trial name
- DISCOVER (NCT02029729)
- Testing
- omaveloxolone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Biogen
Tumors
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Inthis study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with gemcitabine to patients with solid tumours.
- Trial name
- NCT00372437
- Testing
- MGCD0103, Gemcitabine
- Where
- 8 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Mirati Therapeutics Inc.
Solid Tumors Refractory To Standard Therapy, Neoplasms
Kanglaite Injection Phase I Study
The Kanglaite Injection (KLT)is a novel broad spectrum anti-cancer injection produced from traditional Chinese medicinal herbs (the Coix Seed).
- Trial name
- NCT00031031
- Testing
- Kanglaite Injection (KLT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- KangLaiTe USA
Solid Tumours
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
The study design was an open-label Phase II pediatric clinical study. The purpose of Study X2203 was to identify any efficacy signal in subjects with the disease subtypes under study, when treated with pazopanib monotherapy.
- Trial name
- NCT01956669
- Testing
- Pazopanib
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasm Malignant
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Primary Objective: To assess the effect of SAR302503 (500 mg) administered as 14-day repeated doses on the QTcF interval compared to 1-day placebo in patients with advanced solid tumors.
- Trial name
- NCT01836705
- Testing
- SAR302503 (TG101348), Panolosetron
- Where
- 10 sites in United States, Belgium
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Advanced Solid Tumors, Ovarian Cancer
A Study of PHST001 in Advanced Solid Tumors
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination…
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
- Trial name
- NCT06840886
- Testing
- PHST001, Paclitaxel, Topotecan
- Where
- 20 sites in United States
- Volunteers
- 426 people
- Sponsor
- Pheast Therapeutics
Solid Tumors
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of YYB101, HGF-neutralizing humanized Mab, in advanced solid tumors patients who are refractory to standard…
- Trial name
- NCT02499224
- Testing
- YYB101
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- CellabMED
Ewing Sarcoma, Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults…
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma
- Trial name
- NCT03709680
- Testing
- Palbociclib, Temozolomide, Irinotecan
- Where
- 84 sites in United States, Brazil and 11 more
- Volunteers
- 128 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or…
- Trial name
- NCT06132503
- Testing
- LP-284
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Lantern Pharma Inc.
Solid Tumor Malignancies, Lymphoma
Evaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and Lymphoma
This clinical study is investigating a new experimental medicine called LB-208, developed for the treatment of advanced solid tumors and lymphomas in adult patients whose disease has relapsed, not responded to treatment, or for…
- Trial name
- SERONCO-1 (NCT07914348)
- Testing
- LB-208
- Where
- Spain
- Volunteers
- 57 people
- Sponsor
- Leukos Biotech S.L.